These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH. Ann Hematol; 2019 Sep 26; 98(9):2163-2177. PubMed ID: 31243569 [Abstract] [Full Text] [Related]
11. Transplantation of solid organ recipients shedding Epstein-Barr virus DNA pre-transplant: A prospective study. Verghese PS, Schmeling DO, Filtz EA, Grimm JM, Matas AJ, Balfour HH. Clin Transplant; 2017 Nov 26; 31(11):. PubMed ID: 28915342 [Abstract] [Full Text] [Related]
17. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P. Transpl Infect Dis; 2009 Oct 26; 11(5):393-9. PubMed ID: 19497070 [Abstract] [Full Text] [Related]
18. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Hart M, Thakral B, Yohe S, Balfour HH, Singh C, Spears M, McKenna RW. Am J Surg Pathol; 2014 Nov 26; 38(11):1522-9. PubMed ID: 25007145 [Abstract] [Full Text] [Related]